Enterprise Value
-35.41M
Cash
335.7M
Avg Qtr Burn
-79.14M
Short % of Float
11.88%
Insider Ownership
5.88%
Institutional Own.
83.22%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roxadustat (ROW) Details Chronic kidney disease, Anemia | Approved Quarterly sales | |
Roxadustat Details Chemotherapy Induced Anemia | sNDA Submission | |
Phase 3 Data readout | ||
Pamrevlumab Details Duchenne muscular dystrophy | Phase 3 Update | |
Roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
Pamrevlumab Details Pancreatic cancer, Cancer | Phase 2/3 Data readout | |
FG - 3246 (ADC) Details Cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
Roxadustat (U.S.) Details Chronic kidney disease, Anemia | Failed Discontinued | |
Pamrevlumab Details COVID-19, Infectious disease | Failed Discontinued | |
Pamrevlumab Details Idiopathic pulmonary fibrosis | Failed Discontinued |